Interferon alpha and auto-immunity;Interféron alpha et auto-immunité

Revue de Medecine Interne

Volumn 23, Issue SUPPL. 4, 2002, Pages 501S-510S

  Papo, Thomas ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Auto immunity; Interferon alpha

Indexed keywords

ACTIN ANTIBODY; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA ANTIBODY; RECOMBINANT ALPHA INTERFERON;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; DENDRITIC CELL; GRAVES DISEASE; HASHIMOTO DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LOW DRUG DOSE; NONHUMAN; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL;

EID: 17444441784     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00666-5     Document Type: Article

References (108)

1. Proctor SJ, Carey P, Stark A, Finney R, Saunders P, Summerfield G, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon. Blood 1989;74:1894-7.
2. Nicolas JF, Thivolet J. Interferon alpha therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 1989;321:1550-1.
3. Shiozawa S, Morimoto I, Tanaka Y, Shiozawa K. A preliminary study on the interferon alpha treatment for xerostomia of Sjögren syndrome. Br J Rheumatol 1993;32:52-4.
4. Black CM, Silman AJ, Herrick Al, Denton CP, Wilson H, Newman J, et al. Interferon alpha dœs not improve outcome at one year in patients with diffuse cutaneous scleroderma: Results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 1999;426:299-305.
5. O'Duffyjd, Calamia K, Cohen S, Goronzy JG, Herman D, Jorizzo J, et al. Interferon alpha treatment of Behcet's disease. J Rheumatol 1998;25:1938-44.
6. Bolay H, Karahndak R, Aybay C, Candemin H, Varli K, Irnir T, et al. Alpha interferon treatment in myasthenia gravis. Effects on natural killer cells. J Neuroimmunol 1998;82:109-15.
7. Kimata H, Akiyama Y, Kubota M, Fushuro F. Interferon alpha treatment for severe atopic dermatitis. Allergy 1995;50:837-40.
8. Gasche C, Reinisch W, Vogelsang H, Potzi R, Markis A, Micksche M, et al. Prospective evaluation of interferon alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995;40:800-4.
9. Papo T, Piette JC, Le Thi Huong D, Godeau P. Interféron alpha et auto-immunité. Ann Med Interne 1993;144:357-66.
10. Friedman RL, Stark GR. Alpha interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 1985;314:637-9.
11. Giacomini P, Fraioli R, Calabro AM, Di Filippo F, Natali PG. Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res 1991;51:652-6.
12. Guerin V, Todd I, Hammond LJ, Bottazzo GF. Suppression of HLA class II expression on thyrocytes by interferon alpha 1. Clin Exp Immunol 1990;79:341-5.
13. Luft T, Pang KC, Thomas E, Hertzog P, Hart DNJ, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998;161:1947-53.
14. Miossec P. Cytokine-induced auto-immune disorders. Drug safety 1997;17:93-104.
15. Belardelli P, Gresser I. The neglected role of type I interferon in the T-cell response: Implications of its clinical use. Immunol Today 1996;17:369-72.
16. Fairweather D, Rose NR. Type I diabetes: Virus infection or auto-immune disease? Nat Immunol 2002;3:338-40.
17. Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996;157:522-8.
18. Karray S, Delfraissy JF, Merle-Beral H, Wallon C, Debre P, Galanaud P. Positive effects of interferon alpha on B cell-type chronic lymphocytic leukemia proliferative response. J Immunol 1988;140:774-8.
19. + and CD5-B cells of patients with systemic lupus erythematosus. J Clin Invest 1990;85:238-47.
20. Panem S, Check J, Henriksen D, Vilcek J. Antibodies to alpha interferon in a patient with systemic lupus erythematosus. J Immunol 1982;129:1-3.
21. Karlsson-Parra A, Burman P, Hagberg H, Oberg K, Alm G, Klareskog L, et al. Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon alpha (IFN-alpha). Clin Exp Immunol 1990;81:72-5.
22. Magnone M, Holley JL, Shapiro R, Scantleburry V, McCauley J, Jordan M, et al. Interferon alpha induced acute renal allograft rejection. Transplantation 1995;59:1068-70.
23. Gadano AC, Mosnier JF, Durand F, Martinot-Peignoux M, Marcellin P, Degott C, et al. Alpha interferon induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995;59:1627-9.
24. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for reccurrent HCV infection in liver-transplant recipients. N Engl J Med 1994;330:1160-1.
25. Browett PJ, Nelson J, Tiwari S. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukemia postallogeneic bone marrow transplantation. Bone Marow Tranplant 1994;14:641-4.
26. Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of auto-immune disease in patients receiving alpha interferon therapy. Cancer 1990;65:2237-42.
27. Figlin RA, DE Kernian JB, Mukamel E, Palleroni A, Itri LM, Sarna GP. Recombinant interferon alpha 2 in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 1988;6:1604-10.
28. Mayet WJ, Hess G. Gerken G, Rossol S, Voth R, Manns M. Meyer zum Buschenfelde KH. Treatment of chronic type B hepatitis with recombinant alpha interferon induces autoantibodies not specific for auto-immune chronic hepatitis. Hepatology 1989;10:24-8.
29. Saracco G, Touscoz A, Durazzo M, Rosina F, Donegani E, Chiandussi L, et al. Autoantibodies and response to alpha interferon in patients with chronic viral hepatitis. J Hepatol 1990;11:339-43.
30. Gregorio G, Jones H, Chouduri K, Vegnente A, Bortolotti F, Mieli-Vergani G, et al. Autoantibody prevalence in chronic hepatitis B virus infection: Effect of interferon alpha. Hepatology 1996;24:520-3.
31. Steis RG, Smith YW, Urba WJ, Venzon DJ, Longo DL, Barney R, et al. Loss of interferon antibodies during prolonged continuous interferon alpha 2a therapy in hairy cell leukemia. Blood 1991;4:792-8.
32. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986;4:234-43.
33. Ronnblom LE, Alm GV, Oberg KE. Autoimmunity after alpha interferon therapy for malignant carcinoid tumors. Ann Int Med 1991;115:178-83.
34. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10.
35. Becker CB, Winckler B, Klingert S, Bracker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994;73:1621-4.
36. Chung A, Older SA. Interferon alpha associated arthritis. J Rheumatol 1997;24:1844-5.
37. Arai H, Tanaka M, Ohta K, Kojo T, Nijima K, Imawari M. Symptomatic myopathy associated with interferon therapy for chronic hepatitis C. Lancet 1995;345:582.
38. Segawa F, Shmizu Y, Saito E, Kinoshita M. Behcet's disease induced by interferon therapy of chronic myelogenous leukemia. J Rheumatol 1995;22:1183-4.
39. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alpha interferon therapy. J Hepatol 1996;95:972-5.
40. Akard LP, Hoffman R, Elias L, Saiers JH. Alpha interferon and immune hemolytic anemia. Ann Intern Med 1986;105:306.
41. Mangan KF, Zidar B, Shadduk RK, Zeigler Z, Winkelstein A. Interferon-induced aplasia: Evidence for T-cell mediated suppression of hematopoiesis and recovery after treatment with horse anti-human thymocyte globulin. Am J Hematol 1985;19:401-13.
42. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon alpha therapy. J Rheumatol 1994;21:350-2.
43. Parodi A, Semino M, Gallo R, Rebora A. Bullous eruption wtih circulating pemphigus-like antibodies following interferon alpha therapy. Dermatology 1993;186:155-7.
44. Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995;132:474-8.
45. Scheinbenbogen C, Hunstein W, Keilholz U. Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer 1994;30A:1209-11.
46. Dalakos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tisanos EV. A prospective evaluation of dermatological side-effects during alpha interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998;10:933-9.
47. Quesada JR, Gutterman JU. Psoriasis and alpha interferon. Lancet 1986;342:1466-8.
48. Sangster G, Kaye SB, Calman BC, Toy JL. Cutaneous vasculitis associated with interferon. Eur J Cancer Clin Oncol 1983;19:1647-9.
49. Larrey D, Marcellin P, Freneaux E, Pessayre D, Benhamou JP. Exacerbation of multiple sclerosis after the administration of recombinant human interferon alpha. JAMA 1989;261:2065.
50. Batocchi AP, Evoli A, Servidei S, Palmisani MT, Apollo F, Tonali P. Myasthenia gravis during interferon alfa therapy. Neurology 1995;45:383.
51. Kukamura S, Ishikura H, Kobayashi S. Bone marrow necrosis and the Lambert-Eaton syndrome associated with interferon alpha treatment. N Engl J Med 1998;338:199-200.
52. Fentiman IS, Balkwill FR, Thomas BS, Russel MJ, Todd I, Bottazzo GF. An auto-immune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988;24:1299-303.
53. Schultz M, Muller R, von zur Mulhen A, Brabant G. Induction of hyperthyroidism by interferon alpha 2b. Lancet 1989;345:1452.
54. Mathieu E, Fain O, Sitbon M, Thomas M. Diabète auto-immun après traitement par interféron alpha. Presse Med 1995;24:238.
55. Di Cesare E, Previti M, Russo F, Brancatelli S, Ingemi MC, Scloglio R, et al. Interferon alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Dig Dis Sci 1996;41:1672-7.
56. Krug J, Fritzsch J, Aust G. Induction of insulin antibodies and insulin allergy under alpha interferon treatment of renal cell carcinoma in a patient with insulin-treated diabetes mellitus. Int Arch Allergy Immunol 1995;106:169-72.
57. Papo T, Marcellin P, Bemuau J, Durand F, Poynard T, Benhamou JP. Auto-immune chronic hepatitis exacerbated by alpha interferon. Ann. Int Med 1992;116:51-3.
58. Vento S, Di Perri G, Garofano T, Cosco L, Concia E, Ferraro T, et al. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet 1989;345:926.
59. D'Amico E, Paroli M, Fratelli V, Palazzi C, Bamaba V, Callea F, et al. Primary biliary cirrhosis induced by interferon alpha therapy for hepatitis C infection. Dig Dis Sci 1995;40:2113-6.
60. Lederer E, Truong L. Unusual glomerular lesion in a patient receiving long-term interferon treatment. Am J Kidney Dis 1992;20:516-8.
61. Abdi EA, Gia-Kahn N, Ludwig RN, Dickout WJ. Pulmonary sarcoidosis following interferon therapy for advanced renal cancer. Cancer 1987;59:896-900.
62. Ammarota G, Cuoco L, Cainci R, Pandolfi F, Gasbarrini G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 2000;356:1494-5.
63. Veerabagu MP, Finkelstein SD, Rabinovitz M. Granulomatous hepatitis in a patient with chronic hepatitis C treated with interferon alpha. Dig Dis Sci 1997;42:1445-8.
64. Kanda Y, Shigeno K, Kinoshita N, Nakao K, Yano M, Matsuo H. Sudden hearing loss associated with interferon. Lancet 1994;343:1134-5.
65. Guyer DR, Tiederman J, Yannuzzi LA, Slakter JS, Parke D, Kekkey J, et al. Interferon-associated retinopathy. Arch Ophtalmol 1993;11:350-6.
66. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon alpha. Am J Med 1996;172:482-7.
67. Chedin P, Chanson P, Duranteau L, Guillausseau PJ, Lubetzki J. Dysthyroïdies chez les malades traités par interféron alpha. Presse Med 1994;23:1659-63.
68. Fattovitch G, Giustina G, Favarrato S, Ruol. A survey of adverse events in 11 241 patients with chronic viral hepatitis treatedwith alfa interferon. J Hepatol 1996;24:38-47.
69. Fenfiman IS, Thomas BS, Balkwill FR, Rubens RD, Haywardjl. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985;337:1166.
70. Burman P, Totterman TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metabol 1986;63:1086-90.
71. Marcellin P, Pouteau M, Baudin E, Colas-Linhart N, Degos F, Erlinger S, et al. Thyroid dysfunction induced by recombinant alpha interferon in patients with chronic hepatitis C: A prospective study. Hepatology 1991;14:77 [abstract].
72. Lazarus JH, Burr ML, McGregor AM, Weetman AP, Ludgate M, Woodhead JS, et al. The prevalence and progression of auto-immune thyroid disease in the elderly. Acta Endocrinol 1984;106:199-202.
73. Weijl NI, Van der Harst D, Brand A, Kooy Y, van Luxemburg S, Shcroder J, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993;11:1376-83.
74. Deutsch M, Dourakis S, Manesis EK, Gioustozy A, Hess G, Horsch A, Hadziyanis S. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997;26:206-10.
75. Fernandez-Sotto L, Gonzalez A, Escobar-Jimenez F, Vasquez R, Ocete E, Olea N, et al. Increased risk of auto-immune thyroid disease in hepatitis C vs hepatitis B before, during and after discontinuing interferon therapy. Arch Intern Med 1998;158:1445-8.
76. Papo T, Oksenhendler E, Izembart M, Leger A, Clauvel JP. Antithyroid hormone antibodies induced by interferon alpha. J Clin Endocrinol Metab 1992;75:1484-6.
77. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999;17:529-33.
78. Kanayama Y, Inariba TK, Negoro N, Akamura M, Takeda T, Inoue T. Possible involvement of interferon alpha in the pathogenesis of fever in systemic lupus erythematosus. Ann Rheum Dis 1989;48:861-3.
79. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus have a circulating inducer of interferon alpha production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999;115:196-202.
80. Schattner A. Interferons and autoimmunity. Am J Med Sc 1988;295:532-44.
81. Ramirez F, Williams RC, Sibbitt WL, Searles MRP. Immunoglobulin from systemic lupus erythematosus serum induces interferon release by normal mononuclear cells. Arthritis Rheum 1986;29:326-35.
82. Sergiescu D, Cerutti I, Efthymiou E, Kahan A, Chany C. Adverse effects of interferon treatment on the life span of NZB mice. Biomedicine 1979;31:48-51.
83. Gresser I, Maury C, Tovey M, Morel-Maroger L, Pontillon F. Progressive glomerulonephritis in mice treated with interferon preparations at birth. Nature 1976;263:420-2.
84. Schattner A, Duggan D, Naparstek Y, Schwartz RS. Effects of interferon alpha on the expression of a lupus idiotype in normal humans. Clin Immunol Immunopathol 1986;38:327-36.
85. Blanco P, Palucka AK, Gill M, Pascual V, Bancherau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001;294:1540-3.
86. Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer 1991;68:1536-7.
87. Sacchi S, Kantarjian H, O'Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7.
88. Garcia-Porrua C, Gonzalez-Gay MA, Fernandez-Lamelo F, PazCarreira JM, Lavilla E, Gonzalez-Lopez MA. Simultaneous development of SLE-like syndrome and auto-immune thyroiditis following alpha interferon treatment. Clin Exp Rheumatol 1998;16:107-8.
89. Wandl UB, Nagel-Hiemke M, May D, Kreuzfelder E, Kloke O, Kranzhoff M, et al. Lupus-like auto-immune disease induced by interferon therapy for myeloproliferative disorders. Clin Immunol Immunopathol 1992;65:70-4.
90. Preble OT, Rothko K, Klippel JH, Friedman RM, Johnston MI. Interferon-induced 2′-5′ adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med 1983;157:2140-6.
91. Nicolas JF, Thivolet J. Interferon alpha therapy in severe unresponsive subacute cutaneous lupus erythematosus. N Engl J Med 1989;321:1550-1.
92. Thivolet J, Nicolas JF, Kanitakis J, Lyonnet S, Chouvet B. Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus. Br J Dermatol 1990;122:405-9.
93. Becker JC, Winclker B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994;73:1621-4.
94. Durand JM, Quiles N, Kaplanski G. Thrombosis and recombinant interferon alpha. Am J Med 1993;95:115-6.
95. Jadoul M, Piessevaux H, Ferrant A, Cosyns JP, van Ypersele de Strihou G. Renal thrombotic microangiopathy in patients with chronic myelogenous leukemia treated with interferon alpha 2b. Nephrol Dial Transplant 1995;10:111-3.
96. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of "auto-immune" hepatitis. Hepatology 1987;7:1333-9.
97. Ruiz-Moreno M, Rua MJ, Carreno V, Quiroga JA, Manns M. Meyer zum Buschenfelde KH. Auto-immune chronic hepatitis type 2 manifested during interferon therapy in children. J Hepatol 1991;12:265-6.
98. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. N Engl J Med 1989;321:1501-6.
99. Mishiro S, Hoshi Y, Takeda K, Yoshikawa A, Gotanda T, Takahashi K, et al. Non-A, non-B hepatitis specific antibodies directed at a host-derived epitope: Implication for an auto-immune process. Lancet 1990;342:1400-3.
100. Michel G, Ritter A, Gerken G, Meyer ZUM, Buschenfelde KH, Decker H, et al. Anti-GOR and hepatitis C virus in auto-immune liver diseases. Lancet 1992;344:267-9.
101. Kerkar N, Ma Y, Hussain M, Muratori L, Targett C, Williams R, Bianchi FB, et al. A novel assay for detecting antibodies to cytochrome P4502D, the molecular target of liver kidney microsomal antibody type 1. J Immunol Methods 1999;223:227-35.
102. Duclos Vallee JC, Nishioka M, Hosomi N, Arima K, Leclerq K, Bach JF, et al. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: Follow-up by a quantitative radioligand assay for CYP2D6 antibody detection. J Hepatol 1998;28:965-70.
103. Vento S, Cainelli F. Renzini C, Concia E. Auto-immune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997;349:1298-9.
104. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al. Serum autoantibodies in chronic hepatitis C: Comparison with auto-immune hepatitis and impact on the disease profile. Hepatology 1997;26:561-6.
105. Durelli L, Bongianni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Interferon treatment for multiple sclerosis: Autoimmune complications may be lethal. Neurology 1998;50:570-1.
106. Bellary S, Schiano T, Hartman G, Black M. Chronic hepatitis with combined features of auto-immune chronic hepatitis and chronic hepatitis C: Favorable response to prednisone and azathioprine. Ann Intern Med 1995;123:32-4.
107. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent auto-immune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108:1770-7.
108. Kamayoglu S, Cakaloglu Y, Demir K, Turkoglu S, Badur S, Gurel S, et al. Is severe cryptogenic chronic hepatitis similar to auto-immune hepatitis? J Hepatol 1998;28:78-83.